Sabin株脊髓灰质炎灭活疫苗宿主细胞DNA残留量检测方法研究

目的 建立Sabin株脊髓灰质炎灭活疫苗Vero细胞DNA残留量的检测方法.方法 提取Vero细胞基因组DNA,制备地高辛标记探针.比较样品不同处理方式的检测差异.对建立的残留DNA检测方法进行特异性、灵敏度和稳定性验证.结果 Vero细胞基因组DNA的质量浓度为295 μg/ml,260nm与280nm波长处的吸光度比值为1.88.探针灵敏度达到0.01 pg/μl.采用苯酚抽提方式处理DNA参考品,检测灵敏度为1 ng;而用碘化钠处理DNA参考品,灵敏度达到10 pg.特异性检测表明,探针与非同源DNA无杂交.灵敏度和稳定性检测结果显示,探针于-70℃保存9个月,灵敏度仍为10 pg.结论 建立了Sabin株脊髓灰质炎灭活疫苗Vero细胞DNA残留量的检测方法.采用碘化钠提取DNA,回收率高,操作简单,适用于Vero细胞的残留DNA检测.     

磁珠法结合定量PCR检测肠道病毒71型灭活疫苗中宿主细胞DNA残留量的验证及应用

目的  对磁珠法结合定量PCR（quantitative PCR,qPCR）检测肠道病毒71型灭活疫苗〔非洲绿猴肾细胞（Vero细胞）〕（EV71疫苗）中宿主DNA残留量进行适用性验证及应用。方法  利用微磁珠与蛋白溶液中DNA的特异性结合,来提取样品中残留的Vero细胞DNA。将已知浓度Vero细胞DNA对照系列稀释后,作为标准品DNA与提取的DNA同时进行qPCR扩增。根据标准品DNA的循环阈值与浓度之间的线性关系,对未知样品中残留DNA进行定量分析。结果  标准品检测范围在0.03～3 000.00 pg/反应。该方法的标准曲线决定系数≥0.98,扩增效率在90%～110%。质控样品回收率在50%～150%,相对标准偏差均小于30%。实验结果的各项参数均在要求范围内。结论  磁珠法可解决残留DNA检测中样品前处理的技术难点,qPCR能够简便、快速、准确地对生产过程样品的EV71疫苗中DNA残留量进行定量测定。适用于EV71疫苗中DNA残留量的检测及疫苗生产过程和其成品的质量控制,对其他以Vero细胞为基质的病毒性疫苗质量控制具有借鉴意义。     

实时荧光定量PCR法检测门冬氨酸鸟氨酸原料药中毕赤酵母菌DNA残留量

目的 建立可定量检测门冬氨酸鸟氨酸原料药中毕赤酵母菌DNA残留量的实时荧光定量PCR方法。方法 采用宿主细胞残留DNA样本前处理试剂盒（磁珠法）提取毕赤酵母菌DNA,利用毕赤酵母残留DNA检测试剂盒（PCR-荧光探针法）进行扩增反应,绘制标准曲线,建立毕赤酵母菌DNA残留量的Real-time PCR检测方法,并验证其准确性和精密性。结果 毕赤酵母菌DNA质量浓度在0.03~300 pg·μL^-1内线性良好（r>0.99）,定量限为0.03 pg·μL^-1;应用该法对3批门冬氨酸鸟氨酸原料药进行测定,毕赤酵母菌DNA残留量均远低于每剂10 ng。结论 该方法可用于门冬氨酸鸟氨酸原料药中毕赤酵母菌DNA残留量的定量测定。     

荧光定量PCR法测定重组人干扰素α2b原液中宿主DNA的残留

目的建立重组人干扰素α2b原液中宿主DNA残留量测定的方法并进行验证,用于对该产品的质量控制。方法通过wako DNA提取试剂盒提取干扰素原液中的宿主残留DNA,再利用SYBRGreen染料法对样品和标准DNA进行定量PCR测定,根据标准曲线对样品中的DNA残留量分析。对建立的方法进行引物特异性以及结果准确性和精密性的验证,同时对企业提供的3批干扰素原液中的残留DNA测定。结果该方法检测假单胞菌基因组DNA的最低准确定量浓度可达12 fg/μL,DNA含量在12 fg/μL~120 ng/μL范围内线性良好,标准曲线的相关系数r=0.998;wako DNA提取试剂盒提取不同量的加标样品回收率均在50%~200%范围内;该方法检测3批干扰素原液的DNA残留量均低于标准限度,符合《中国药典》三部2010年版和2015年版中关于假单胞菌产重组人干扰素α2b原液中宿主DNA残留量的要求。结论 wako DNA提取试剂盒能解决干扰素原液中样品前处理的技术难点,与定量PCR法结合能够简便、快速、准确地对干扰素原液中残留的DNA定量测定。     

Sabin株脊髓灰质炎灭活疫苗Vero细胞DNA残留定量PCR检测法的验证

目的  验证Sabin株脊髓灰质炎灭活疫苗中Vero细胞DNA残留定量PCR（quantitative PCR,qPCR）检测法。方法  用试剂盒提取Sabin株脊髓灰质炎灭活疫苗原液的DNA,采用qPCR法检测Vero细胞DNA,并验证方法的线性、专属性、准确性、精密度、耐用性及定量限;同时采用DNA探针杂交法检测样品。结果  qPCR检测Vero细胞DNA标准曲线在0.003 0~300.000 pg/μl之间线性良好;对Hep-2细胞、大肠埃希菌、酵母细胞DNA均无扩增反应;高、中、低浓度样品加标回收率在50%~150%,准确性良好;定量检出限为0.003 0 pg/μl;精密度良好（相对标准偏差＜15%）;反应体系配制好后置于2~8 ℃ 30 min后进行检测,相对标准偏差＜15%,耐用性良好。DNA探针杂交法与qPCR结果均小于0.1 pg/μl。 结论  qPCR检测Sabin株脊髓灰质炎灭活疫苗中Vero细胞DNA残留具有良好的线性、专属性、准确性、精密度和耐用性,可适用于该项检测。     

荧光定量PCR检测重组人干扰素α2b中宿主基因组的残留DNA

目的 采用荧光定量PCR法检测注射用重组人干扰素α2b半成品中宿主基因组的残留DNA.方法 选择重组人干扰素α2b工程菌的宿主菌23S核糖体RNA基因为模板设计扩增引物,建立基于SYBR Green Ⅰ荧光染料的荧光定量PCR检测法.结果 宿主基因组DNA的量与荧光定量反应的Ct(循环阈值)值呈良好的线性关系(r~2=0.9803).结论 所用方法操作简便、快速,可用于重组人干扰素α2b制备过程中的质量监控及半成品的检定.     

重组hPK-5质粒DNA基因治疗制剂的质量标准研究

目的:建立重组 hPK-5质粒 DNA 基因治疗制剂的质量标准和检测方法。方法:采用限制性酶切图谱分析鉴定质粒DNA 结构和 PCR 法鉴定插入的 hPK-5基因作鉴别试验;采用分光光度法测定质粒 DNA 含量和 A_(260)/A_(280)比值;采用琼脂糖凝胶电泳法分析质粒 DNA 的超螺旋构象比例和残留 RNA 含量;采用阴离子交换色谱法分析 HPLC 纯度;采用 ELISA 法测定hPK～5蛋白的表达量;采用内皮细胞迁移法测定 hPK-5蛋白的生物学活性。结果:重组质粒 DNA 的限制性酶切片段大小与理论值一致;插入基因 PCR 扩增片段大小与理论值相符;质粒 DNA 含量为1.12 mg·mL~(-1);A_(260)/A_(280)比值为1.83;琼脂糖凝胶电泳法测定超螺旋构象质粒的比例为95.4%;HPLC 测定超螺旋质粒 DNA 占93.8%,开环质粒 DNA 占6.2%,琼脂糖凝胶电泳法测定木检出 RNA 残留;没有检出其他杂质;以2μg重组 hPK-5质粒转染5×10~5Hela 细胞48 h 后,2 mL 培养上清中 hPK-5蛋白浓度为109 ng·mL~(-1);以培养上清进行内皮细胞迁移试验,转染重组 hPK-5质粒 DNA 组迁移的内皮细胞数明显少于对照绀(P<0.05)。其他项目均符合相应的规定。结论:建立了重组 hPK-5质粒 DNA 基因治疗制剂的检定方法及其质量标准,为有效控制该类产品的质量打下基础。     

地高辛标记探针检测重组人p43蛋白宿主DNA残留量的研究

目的:建立重组人p43蛋白原液中宿主DNA残留量的检测方法。方法:以重组人p43工程菌基因组DNA为模板,制备地高辛标记的探针,并以此探针与阳性对照品及供试品进行杂交及显色反应。结果:3批次重组人p43蛋白原液中每人份剂量的宿主DNA残留量均小于10 ng。结论:该方法灵敏度高,特异性强,重复性好,操作安全简便,可用于重组人p43制备过程中的原液检定及质量监控。     

生物制品中宿主细胞残留DNA检测的研究进展

宿主细胞残留DNA是指可能出现于生物制品中的来自宿主细胞的DNA片段。用传代细胞株生产的生物制品,其宿主细胞残留DNA可能会传递肿瘤或病毒相关基因,存在潜在的危险性。各国药品监督管理机构对宿主细胞残留DNA的残留量有着严格的限度控制,同时各国药典也提供数种经典的检测方法。建立合适的宿主细胞残留DNA检测方法有助于监测生产工艺,确保生物制品的安全性和质量。此文对宿主细胞残留DNA潜在的危害、国内外监管机构对宿主细胞残留DNA检测标准和检测方法以及各方法的特点及研究进展做一综述。     

生物制品宿主细胞残留DNA检测限定标准及方法浅析

近年来热度骤增的生物制品药物对诸多疾病疗效斐然,在药品市场中所占比重也是节节攀升。于是生物制品与之俱来的生物安全性问题被渐渐提上日程,其中宿主细胞残留DNA由于可能会传递肿瘤或病毒相关基因,存在潜在的危险性,各国药品监督管理机构对其残留量有着严格的限度控制。同时,各国药典也陆续提供数种关于宿主细胞残留DNA检测经典的方法,目前以实时定量聚合酶链式反应(PCR)方法为最优,因其专一性强、灵敏度高、快速且可实现高通量。本文介绍了一些国内与国外监管机构出台的关于生物制品宿主细胞残留DNA检测的限定规定,并对现有的常见检测方法进行描述、总结和比较。     

Selective binding to human genomic sequences of two synthetic analogues structurally related to U‐71184 and adozelesin

In this paper, we analyse the in vitro sequence‐selectivity of two synthetic analogues of U‐71184 and adozelesin by polymerase chain reaction (PCR) performed on human genomic DNA. In addition, Dnase footprinting and nucleotide sequence analysis on arrested‐PCR products were performed to confirm sequence‐selective binding. Finally, the antitumor effects were studied in vitro on human leukemic L1210 cells. The binding activity of the two newly synthesized compounds to human gene sequences was compared with the CC‐1065 analogue U‐71184, the A+T sequence‐selective drug distamycin and the G+C sequence‐selective drugs mithramycin and chromomycin. As molecular model systems for in vitro DNA‐binding studies we used the human estrogen receptor gene and the Ha‐ras oncogene. In some experiments the PCR approach was performed using as target DNA a portion of the long terminal repeat (LTR) of the human immunodeficiency type 1 virus (HIV‐1). These genomic regions contain sequences that are different with respect to A+T/G+C ratios, being the upstream sequence of the human estrogen receptor gene A+T rich, while the Ha‐ras and HIV‐1 LTR sequences contain G+C–rich regions. The first conclusion that can be drawn from the experiments reported in our paper is that the two newly synthetized analogues of U‐71184 and adozelesin inhibit PCR‐mediated amplification of genomic regions in a sequence‐dependent manner. A second conclusion of our experiments is that these compounds are active inhibitors of tumor cell growth in vitro. Drug Dev. Res. 46:96–106, 1999. © 1999 Wiley‐Liss, Inc.     

Hexamethylene bisacetamide stimulates the expression of human immunodeficiency virus long terminal repeat sequences in rat and human fibroblasts.

We have employed a recombinant plasmid, pBHIV1, carrying the long terminal repeat (LTR) sequence of the human immunodeficiency virus-1 (HIV-1) linked to the reporter chloramphenicol acetyl transferase (CAT) gene and to the aminoglycoside phosphotransferase (aph) gene as a selectable marker. We have introduced pBHIV1 in rat 208F and human MRCSV40TGR fibroblasts and obtained stable geneticin resistant RFBHIV1-1 and SVTGHIV1-1 cells, respectively. Both transfectant cells express CAT activity from the HIV LTR promoter. The response to anti-neoplastic drug hexamethylene bisacetamide (HMBA) was studied on the LTR regulated CAT activity in both cell lines. It was found that HMBA at 5mM concentration stimulates the expression of CAT from the HIV LTR in rat and human cells by 28- and 1.9-fold, respectively.     

Taqman real-time PCR assay based on ORFV024 gene for rapid detection of orf infection

Abstract

In this study, a TaqMan real-time polymerase chain reaction (PCR) assay was developed to detect and quantify orf virus (ORFV) DNA in infected cell culture and clinical samples. Primers and probes were designed to amplify an 87?bp fragment DNA based on the sequence of ORFV024 gene encoding an NF-κB inhibitor of orf virus. The assay was highly specific and sensitive for ORFV DNA and no cross-reactions were detected with any other poxviruses; the sensitivity was 5?fg or 15 copies of ORFV genomic DNA. Both intra- (1.490?±?1.261%) and inter-assay (1.958?±?0.568%) variabilities were within the acceptable range, indicating the high efficiency and reproducibility of the assay. Further, the assay has shown a relative diagnostic sensitivity and specificity of 100%, when compared to B2L gene-based semi-nested PCR. The assay is simple, rapid, specific and sensitive with a wide potential for rapid field diagnosis of orf in sheep and goats.     

人破骨细胞分化因子基因启动子报告载体的构建

目的：构建能够报告人破骨细胞分化因子（ODF）基因启动子活性的表达载体。方法：以人基因组DNA为模板，PCR扩增含有ODF基因启动子的2段序列（-2433-1243 bp和-1262-＋100bp）。通过T-A克隆将这2个序列片段分别连接到pGEM-TEasy克隆载体上。利用特定的限制性内切酶位点。将这2个序列片段酶切后进行正确拼接并定向克隆到不含启动子的pEGFP-1报告基因载体上。将该重组质粒pEGFP-1-ODF瞬时转染成骨细胞系UMR106．检测其能否在ODF基因启动子（-2358-＋100bp）的调控下表达报告基因增强型绿色荧光蛋白（EGFP）。结果：pEGFP-1-ODF经酶切鉴定和序列分析证实与设计完全一致。细胞瞬时转染结果表明，pEGFP-1-ODF转染的UMR106能表达EGFP。结论：人ODF基因启动子报告载体的成功构建。为进一步研究ODF基因表达转录水平的调控机制奠定了基础。     

Synthesis, in vitro antiproliferative activity, and DNA-binding properties of hybrid molecules containing pyrrolo[2,1-c][1, 4]benzodiazepine and minor-groove-binding oligopyrrole carriers

The synthesis, biological activity, and DNA-binding properties of a series of four hybrids prepared by combining polypyrrole minor groove binders and pyrrolo[2,1-c][1,4]benzodiazepine (PBD) 13, related to the naturally occurring anthramycin (3) and DC-81 (4), have been described, and structure-activity relationships have been discussed. These hybrids 22-25 contain from one to four pyrrole units, respectively. To investigate sequence selectivity and stability of drug/DNA complexes, DNase I footprinting and arrested polymerase chain reaction (PCR) were performed on human c-myc oncogene, estrogen receptor gene, and human immunodeficiency virus type 1 long terminal repeat (HIV-1 LTR) gene sequences. The antiproliferative activity of the hybrids has been tested in vitro on human myeloid leukemia K562 and T-lymphoid Jurkat cell lines and compared to antiproliferative effects of the natural product distamycin A 1, its tetrapyrrole homologue 17, DC 81 (4), and the PBD methyl ester 12. The results obtained demonstrate that the hybrids 22-25 exhibit different DNA-binding activity with respect to both distamycin A 1 and PBD 12. In addition, a direct relationship was found between number of pyrrole rings present in the hybrids 22-25 and stability of drug/DNA complexes. With respect to antiproliferative effects, it was found that the increase in the length of the polypyrrole backbone leads to an increase of in vitro antiproliferative effects, i.e., the hybrid 25 containing the four pyrroles is more active than 22, 23, and 24 both against K562 and Jurkat cell lines.     

贝母的分子生物学鉴定方法的研究

用ＤＮＡ指纹图谱、ＲＡＰＤ和ＤＮＡ测序等技术鉴定中药材已有不少报道[1～ 5] 。ＤＮＡ的提取和ＰＣＲ扩增是分子生物学最基本的操作步骤之一。但是由于商品药材多数经过加工处理 ,ＤＮＡ可能会受到不同程度的降解 ,再者植物药材中含有的次生代谢产物如多糖很难与ＤＮＡ和ＲＮＡ分开 ,而多糖对酶有抑制作用 ,因此将会影响ＤＮＡ的提取和ＰＣＲ扩增。本文以贝母为研究对象 ,探讨不同ＤＮＡ提取方法、不同扩增条件对ＰＣＲ产物的影响 ,为生药的分子生物学鉴定提供参考。材料与方法1　材料　托里贝母Ｆｒｉｔｉｌｌａｒｉａｔｏｒｔｉｆｏｌ…